ChiTn, a mouse/human chimeric anti-Tn monoclonal antibody, was radiolabeled with iodine-131 (131I) and technetium-99m (99mTc) to assess its biodistribution and internalization in Tn-expressing (Tn+) and wild-type (Tn-) LL/2 lung cancer cells.
Results:
Selective accumulation and gradual internalization of ChiTn were observed in Tn+ cells. Biodistribution in mice with both Tn+ or Tn− lung tumors indicated that the uptake of radiolabeled ChiTn within tumors increased over time. Dual-labeling experiments with 99mTc and 131I showed different biodistribution patterns, with 99mTc exhibiting higher values in the liver, spleen, and kidneys, while 131I showed higher uptake in the thyroid and stomach. However, tumor uptake did not significantly differ between Tn+ and Tn− tumors. To improve tumor targeting, Losartan, an antihypertensive drug known to enhance tumor perfusion and drug delivery, was investigated. Biodistribution studies in Losartan-treated mice revealed significantly higher radiolabeled ChiTn uptake in Tn+ tumors. No significant changes were observed in the uptake of the control molecule IgG-HYNIC™99mTc.
Conclusions:
These findings demonstrate the enhanced tumor targeting of radiolabeled ChiTn in Losartan-treated mice with Tn-expressing lung tumors. They highlight the potential of ChiTn as a theranostic agent for cancer treatment and emphasize the importance of Losartan as an adjunctive treatment to improve tumor perfusion and drug delivery.
Get full access to this article
View all access options for this article.
References
1.
BussNA, HendersonSJ, McFarlaneM, et al.Monoclonal antibody therapeutics: History and future. Curr Opin Pharmacol, 2012; 12:615–622.
2.
HafeezU, GanHK, ScottAM. Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. Curr Opin Pharmacol, 2018; 41:114–121.
3.
KaplonH, ReichertJM. Antibodies to watch in 2021. MAbs, 2021; 13:1860476.
4.
MartineauP, WatierH, PèlegrinA, et al.Targets for MAbs: Innovative approaches for their discovery & validation. MAbs. 2019; 11(5):812–825. doi: 10.1080/19420862.2019.1612691
5.
HakomoriS. Glycosylation defining cancer malignancy: New wine in an old bottle. Proc Natl Acad Sci U S A, 2002; 99:10231–10233.
6.
JuT, OttoVI, CummingsRD, et al.The Tn antigen-structural simplicity and biological complexity. Angew Chem Int Ed Engl, 2011; 50:1770–1791; doi: 10.1002/anie.201002313
7.
HubertP, HeitzmannA, VielS, et al.Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy. Cancer Res, 2011; 71(15):5134–5143; doi: 10.1158/0008-5472
8.
SedlikC, HeitzmannA, VielS, et al.Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen. Oncoimmunology, 2016; 5(7):e1171434; doi: 10.1080/2162402X.2016.1171434
9.
FuC, ZhaoH, WangY, et al.Tumor-associated antigens: Tn antigen, sTn antigen, and T antigen. HLA, 2016; 88(6):275–286; doi: 10.1111/tan.12900
10.
LiuZ, LiuJ, DongX, et al.Tn antigen promotes human colorectal cancer metastasis via H-Ras mediated epithelial-mesenchymal transition activation. J Cell Mol Med, 2019; 23(3):2083–2092; doi: 10.1111/jcmm.14117
11.
da CostaV, van VlietSJ, CarasiP, et al.The Tn antigen promotes lung tumor growth by fostering immunosuppression and angiogenesis. Cancer Lett, 2021; 518:72–81; doi: 10.1016/j.canlet.2021.06.012
12.
Larsson-CallerfeltAK, Andersson SjölandA, HallgrenO, et al.VEGF induces ECM synthesis and fibroblast activity in human lung fibroblasts. Eur Respir J, 2017; 50(Suppl 61):PA1045; doi: 10.1183/1393003.congress-2017.PA1045
13.
KuiperEJ, Van NieuwenhovenFA, de SmetMD, et al.The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS One, 2008; 3(7):e2675; doi: 10.1371/journal.pone.0002675
14.
ZhangJ, ChuM. Differential roles of VEGF: Relevance to tissue fibrosis. J Cell Biochem, 2019; 120:10945–10951.
15.
JainRK. Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia. Cancer Cell, 2014; 26:605–622.
16.
LiuJ, LiaoS, Diop-FrimpongB, et al.TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc Natl Acad Sci U S A, 2012; 109:16618–16623.
17.
ChauhanVP, MartinJD, LiuH, et al.Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun, 2013; 4:2516–2527.
18.
NiaHT, LiuH, SeanoG, et al.Solid stress and elastic energy as measures of tumour mechanopathology. Nat Biomed Eng, 2016; 1:4–29.
19.
StylianopoulosT, MunnLL, JainRK. Reengineering the physical microenvironment of tumors to improve drug delivery and efficacy. Trends Cancer, 2018; 4:292–319.
20.
Diop-FrimpongB, ChauhanVP, KraneS, et al.Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci U S A, 2011; 108:2909–2914.
21.
ZhaoY, CaoJ, MelamedA, et al.Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models. Proc Natl Acad Sci U S A, 2019; 116(6):2210–2219; doi: 10.1073/pnas.1818357116
22.
AndoH, MatsushitaT, WakitaniM, et al.Mouse-human chimeric anti-Tn IgG1 induced anti-tumor activity against Jurkat cells in vitro and in vivo. Biol Pharm Bull, 2008; 31:1739–1744.
23.
WelinderC, BaldetorpB, BorrebaeckC, et al.A new murine IgG1 anti-Tn monoclonal antibody with in vivo antitumor activity. Glycobiology, 2011; 21:1097–1107; doi: 10.1093/glycob/cwr048
24.
ScottAM, WolchokJD, OldLJ, et al.Antibody therapy of cancer. Nat Rev Cancer, 2012; 12:278–287; doi: 10.1038/nrc3236
25.
VacchelliE, GalluzziL, EggermontA, et al.Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology, 2013; 2:e22789; doi: 10.4161/onci.22789
26.
ChauCH, SteegPS, FiggWD, et al.Antibody-drug conjugates for cancer. Lancet, 2019; 394:793–804.
27.
DovganI, KolodychS, KonievO, et al.Antibody-drug conjugates and other nanomedicines: The frontier of gynaecological cancer treatment. Bioconjug Chem, 2019; 30:2483–2501.
28.
SteinerM, NeriD. Antibody-radionuclide conjugates for cancer therapy: Historical considerations and new trends. Clin Cancer Res, 2011; 17:6406–6416.
29.
AudicioP, CastellanoG, TassanoM, et al.[177Lu] DOTA-anti-CD20: Labeling and pre-clinical studies. Appl Radiat Isot, 2011; 69(7):924–928; doi: 10.1016/j.apradiso.2011.01.026
30.
CamachoX, GarcíaMF, CalzadaV, et al.99mTc-labeled bevacizumab via HYNIC for imaging of melanoma. J Anal Oncol, 2014; 3(1):53–64; doi: 10.6000/1927-7229.2014.03.01.9
31.
CamachoX, MachadoCL, GarcíaMF, et al.Technetium-99m- or Cy7-labeled rituximab as an imaging agent for non-Hodgkin lymphoma. Oncology, 2017; 92(4):229–242; doi: 10.1159/000452419
32.
HarsiniS, RezaeiN. Cancer Imaging with Radiolabeled Monoclonal Antibodies. In: Cancer Immunology. (RezaeiN. ed.) Springer: Cham, 2020; pp. 739–760; doi: 10.1007/978-3-030-30845-2_32
33.
LinM, PaolilloV, LeDB et al. Monoclonal antibody based radiopharmaceuticals for imaging and therapy. Curr Probl Cancer, 2021; 45(5):100796; doi: 10.1016/j.currproblcancer.2021.100796
34.
ZhangL, ZhaoS, JiangHet al.Radioimmunotherapy study of 131I-labeled Atezolizumab in preclinical models of colorectal cancer. Eur J Nucl Med Mol Imaging, 2022; 12:70; doi: 10.1186/s13550-022-00939-2
35.
DuattiA. Review on 99mTc radiopharmaceuticals with emphasis on new advancements. Nucl Med Biol, 2021; 92:202–216; doi: 10.1016/j.nucmedbio.2020.05.005
36.
OsinagaE, BayS, TelloD, et al.Analysis of the fine specificity of Tn-binding proteins using synthetic glycopeptide epitopes and a biosensor based on surface plasmon resonance spectroscopy. FEBS Lett, 2000; 469(1):24–28; doi: 10.1016/s0014-5793(00)01248-5
37.
GarcíaMF, CalzadaV, CamachoX, et al.Microwave-assisted synthesis of HYNIC protected analogue for 99mTc labeled antibody. Curr Radiopharm, 2014; 7(2):84–90.
38.
KnightJC, MosleyMJ, KersemansV, et al.Dual-isotope imaging allows in vivo immunohistochemistry using radiolabelled antibodies in tumours. Nucl Med Biol, 2019; 70:14–22; doi: 10.1016/j.nucmedbio.2019.01.010
39.
TassanoM, CabreraM, CamachoX, et al.Simultaneous biodistribution studies of Tc-99m/I-131 labeled antibody with HPGe gamma spectrometry. Eur J Nucl Med Mol Imaging, 2021; 48:423–424.
40.
RaybautP. Spyder-Documentation. 2009. Available from: Pythonhosted.org [Last accessed: October 1, 2023].
41.
McKinneyW. Data Structures for Statistical Computing in Python. In: Proceedings of the 9th Python in Science Conference, Austin, Texas; 2010; pp. 51–56.
CurtiBD. Physical barriers to drug delivery in tumors. Crit Rev Oncol Hematol, 1993; 14:29–39; doi: 10.1016/1040-8428(93)90004-N
47.
SriramanSK, AryasomayajulaB, TorchilinVP. Barriers to drug delivery in solid tumors. Tissue Barriers, 2014; 2:e29528; doi: 10.4161/tisb.29528
48.
LibuttiSK, TamarkinL, NilubolN. Targeting the invincible barrier for drug delivery in solid cancers: Interstitial fluid pressure. Oncotarget, 2018; 9:35723–35725.
49.
JainRK. Barriers to drug delivery in solid tumors. Sci Am, 1994; 271(1):58–65.
50.
AnchordoquyTJ, BarenholzY, BoraschiD, et al.Mechanisms and barriers in cancer nanomedicine: Addressing challenges, looking for solutions. ACS Nano, 2017; 11(1):12–18; doi: 10.1021/acsnano.6b08244
51.
VinodN, KimJH, ChoiS, et al.Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model. Sci Rep, 2021; 11:12871; doi: 10.1038/s41598-021-92460-0
52.
CastroA, BeroisN, MalangaA, et al.Docetaxel in chitosan-based nanocapsules conjugated with an anti-Tn antigen mouse/human chimeric antibody as a promising targeting strategy of lung tumors. Int J Biol Macromol, 2021; 182:806–814; doi: 10.1016/j.ijbiomac.2021.04.054
53.
KuoWY, LinJJ, HsuHJ, et al.Noninvasive assessment of characteristics of novel anti-HER2 antibodies by molecular imaging in a human gastric cancer xenograft-bearing mouse model. Sci Rep, 2018; 8:13735; doi: 10.1038/s41598-018-32094-x
54.
GarcíaMF, ZhangX, ShahM, et al.(99m)Tc-bioorthogonal click chemistry reagent for in vivo pretargeted imaging. Bioorg Med Chem, 2016; 24(6):1209–1215; doi: 10.1016/j.bmc.2016.01.046
55.
MeszarosLK, DoseA, BiaginiSC, et al.Hydrazinonicotinic acid (HYNIC)—Coordination chemistry and applications in radiopharmaceutical chemistry. Inorg Chim Acta, 2010; 363:1059–1069.
56.
GuptaS, BatraS, JainM. Antibody labeling with radioiodine and radiometals. Methods Mol Biol, 2014; 1141:147–157; doi: 10.1007/978-1-4939-0363-4_9
57.
FengY, MeshawR, McDougaldD, et al.Evaluation of an 131I-labeled HER2-specific single domain antibody fragment for the radiopharmaceutical therapy of HER2-expressing cancers. Sci Rep, 2022; 12:3020; doi: 10.1038/s41598-022-07006-9
58.
TolmachevV, OrlovaA, AnderssonK. Methods for radiolabelling of monoclonal antibodies. Methods Mol Biol, 2014; 1060:309–330.
59.
RudnickSI, LouJ, ShallerCC, et al.Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res, 2011; 71:2250–2259; doi: 10.1158/0008-5472.CAN-10-2277
60.
WilliamsL. Comparison of iodine-labeled and indium-labeled antibody biodistributions. Med Phys, 2014; 41:133; doi: 10.1118/1.4887962
61.
PressOW, ShanD, Howell-ClarkJ, et al.Comparative metabolism and retention of Iidine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res, 1996; 56(9):2123–2129.
62.
VivierD, SharmaSK, ZeglisBM. Understanding the in vivo fate of radioimmunoconjugates for nuclear imaging. J Labelled Comp Radiopharm, 2018; 61(9):672–692; doi: 10.1002/jlcr.3628
63.
DeyevSM, VorobyevaA, SchulgaA, et al.Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1. Int J Biol Macromol, 2020; 145:216–225.
64.
HeneweerC, HollandJP, DivilovV, et al.Magnitude of enhanced permeability and retention effect in tumors with different phenotypes: 89Zr-albumin as a model system. J Nucl Med, 2011; 52:625–633.
65.
FangJ, NakamuraH, MaedaH. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev, 2011; 63:136–151.
66.
BörjessonPKE, JauwYWS, BoellaardR, et al.Performance of immuno–positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res, 2006; 12:2133.
67.
KumarV, BoucherY, LiuH, et al.Noninvasive assessment of Losartan-induced increase in functional microvasculature and drug delivery in pancreatic ductal adenocarcinoma. Transl Oncol, 2016; 9(5):431–437; doi: 10.1016/j.tranon.2016.07.004
68.
BonnotteB, GoughM, PhanV, et al.Intradermal injection, as opposed to subcutaneous injection, enhances immunogenicity and suppresses tumorigenicity of tumor cells. Cancer Res, 2003; 63(9):2145–2149.
69.
CiconeF, DenoëlT, GnesinS, et al.Preclinical evaluation and dosimetry of [111In]CHX-DTPA-scFv78-Fc targeting endosialin/tumor endothelial marker 1 (TEM1). Mol Imaging Biol, 2020; 22:979–991; doi: 10.1007/s11307-020-01479-8
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
